December 9-11, 2025 | Boston, MA

www.oligonucleotide-based-therapeutics.com

SAVE $900 BY REGISTERING BEFORE FRIDAY, SEPTEMBER 26

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Oligonucleotide-based Therapeutics Summit

Fine-Tuning RNA Chemistry & Precision Delivery

Enhance Oligonucleotide Efficacy & Safety through Optimizing Chemical Modifications & Delivery Systems to Drive Superior Specificity, Mitigate Off-Target Effects, & Cellular Uptake to Target Undruggable Molecules

Expert Speakers Include:

Hagen Cramer
Chief Technology Officer
QurAlis

Paloma Giangrande
Senior Vice President, Discovery & Translational Biology
Orbital Therapeutics

Cody Dejardins
Senior Director
Dyne Therapeutics

Ganesh Iyer
Chief Executive Officer & Founder
Opprtna Therapeutics

Jack Ostrowski
Director, Protein Sciences
Avidity Biosciences

Meena Indrakanti
Senior Vice President, Translational DMPK & Clinical Pharmacology
Stoke Therapeutics

+1 617 455 4188 info@hansonwade.com

www. oligonucleotide-based-therapeutics.com

hansonwade

Welcome to the Oligonucleotide-based Therapeutics Summit

Oligonucleotide-based Therapeutics Summit

December 9-11, 2025 | Boston, MA

The inaugural **Oligonucleotide-based Therapeutics Summit** is biopharma's definitive forum dedicated to developing more safe and efficacious oligonucleotide therapeutics.

Built in collaboration with industry experts at **Secarna**, **Genentech**, **Novo Nordisk**, **Biogen** and others this industry defining conference will disseminate cutting-edge science to enhance molecule stability and efficacy, minimize off-target effects and unlock new therapeutic potential of previously undruggable targets.

Focussed from discovery through to clinical development, 19+ thought leaders from across pharma and biotech will give you access to unparalleled insights on:

- **Refining Oligonucleotide chemistry and structure** to optimize safety, efficacy, and specific targeting with supporting preclinical and clinical data
- **Overcoming delivery barriers**, to improve efficacy of oligo therapeutics, using advanced technologies- aptamers, platforms, nanoparticles and more
- **Targeting novel and validated but undruggable targets** with oligonucleotides, to overcome the limitations of other drug modalities like ADCs and small molecules by enabling precise gene silencing or modulation at the RNA level

With iterative improvements to oligonucleotide drug design and a better understanding of delivery requirements, heads are being turned by the opportunity for oligonucleotides to be incorporated into multimodal treatment regimens with improved safety, efficacy and patient survival. This is your opportunity to unite with 50+ biotech and pharma scientists and KOLs to **pioneer precision delivery of oligonucleotides**, **target undruggable molecules** and **reduce off-target effects with fine-tuned RNA chemistry**.

What Our Attendees have to Say

"The experience was thoroughly enjoyable due to the great networking opportunities and the relevance of the topics discussed"

Principal Scientist, Alnylam

"The sessions were highly relevant to the challenges currently faced in the industry"

Associate Director, Avidity Biosciences

Key Benefits of Attending

Cracking the Delivery Challenge for Oligos

Uncover the latest advancements in precision delivery and tissue targeting and leave with practical strategies to boost efficacy and reduce off-target effects with **Avidity Biosciences**, **Secarna**, **Dyne Therapeutics** and more.

Innovating Oligo Chemistry & Design

Explore cutting-edge chemical modifications and novel design approaches enhance stability, reduce off-target effects. Unlock new therapeutic possibilities for previously "undruggable" targets with **Stoke Therapeutics** and **Novo Nordisk**.

Mastering CMC for Oligonucleotides

Gain clarity on the evolving CMC landscape for RNA-based modalities. Hear how leading teams are building robust, scalable processes to ensure consistency, compliance, and quality from early discovery through commercial scale-up with **QurAlis**.

Mastering Analytical Challenges in Diastereomer Characterization

Explore how advanced analytical and statistical methods, applied to FDA-approved drugs and synthetic analogues, can overcome limitations in diastereomer assessment and strengthen confidence in oligonucleotide development with leading Professors from the **University of Maryland**.

Addressing Safety & Toxicity Head-On

Explore the latest data, methodologies, and predictive tools for mitigating toxicity risks, and learn how to design safer, more tolerable oligonucleotide therapies from the ground up with **Nanovation**.

+1 617 455 4188 info@hansonwade.com
www. oligonucleotide-based-therapeutics.com

hansonwade

Your World-Class Speaker Faculty

Jack Ostrowski
Director, Protein Sciences
Avidity Biosciences

Kevin Guckian
Senior Director
Biogen

Marcin Kortylewski
Professor, Immuno-Oncology
City of Hope



Cody Desjardins
Senior Director
Dyne Therapeutics

Tama Evron
Director, Platform Discovery
Dyne Therapeutics

David Guay
Vice President, Innovation & Technology
Feldan Therapeutics

Santhosh Kumar Thatikonda
Senior Principal Scientist & Group Lead
Genentech

Utsav Saxena
Head of Systems Biology
Novo Nordisk

Ganesh Iyer
Chief Executive Officer & Founder
Opprtna Therapeutics

Paloma Giangrande
Senior Vice President, Discovery & Translational Biology
Orbital Therapeutics

Hagen Cramer
Chief Technology Officer
QurAlis

Puneet Anand
Senior Principal Scientist
Regeneron

Jean-Christophe Hoflack
Senior Principal Scientist
F Hoffmann-La Roche

Frank Jaschinski
Chief Scientific Officer
Secarna

Meena Indrakanti
Senior Vice President, Translational DMPK & Clinical Pharmacology
Stoke Therapeutics

David Parfitt
Senior Scientist
ProQR Therapeutics

Jace W. Jones
Associate Professor, Department of Pharmaceutical Sciences, School Pharmacy
University of Maryland

Michael P. Cummings
Professor of Biology & Director of the Center for Bioinformatics & Computational Biology
University of Maryland

Pawan Kumar
Director, Oligonucleotide Chemistry
Biomarin

What to Expect:

50+
Attendees

19+
Expert Speakers

1
Scientific Poster Session

2
In Depth Workshops

8+
Hours of Networking

Pre-Conference Workshop Day
Tuesday, December 9

Morning Coffee & Check-in 8.30

Workshop A 9.00

Leveraging Delivery Approaches to Translate Oligonucleotide-Based Therapies for Different Indications

The success of oligonucleotide therapeutics hinges not only on target selection and chemistry but also on delivery strategies that can unlock extrahepatic targets and expand the reach of these modalities. While conjugate-based approaches have driven remarkable progress in hepatocyte delivery, new indications, from neuromuscular diseases to oncology, demand innovative delivery solutions to overcome biological barriers, ensure tissue specificity, and maintain safety.

This interactive workshop will equip you with a deep understanding and overview of delivery innovation, from conjugation technologies and ligand selection to lipid nanoparticles, brain shuttles, and beyond. Through real-world case studies, collaborative problem-solving, and expert-led discussion, you'll leave with actionable strategies to optimize delivery for different tissue targets, reduce off-target risks, and accelerate your program toward clinical success.

This workshop will gather experts to discuss:

- **Understand the Current Delivery Landscape:** Review leading approaches including GalNAc conjugation, LNPs, and novel carrier systems, and their applicability across different tissues
- **Tackle Tissue-Specific Challenges:** Explore practical solutions for crossing biological barriers such as the blood-brain barrier and targeting muscle, adipose tissue, or tumors
- **Plan for Clinical Translation:** Learn how to align delivery strategy with indication, safety requirements, and scalability considerations for late-stage development

Workshop Leaders

Paloma Giangrande
Senior Vice President
Orbital Therapeutic

Kevin Guckian
Senior Director
Biogen

Puneet Anand
Senior Principal Scientist
Regeneron

Networking & Light Lunch 12.00

Workshop B 1.00

Bioanalytical and Statistical Methods to Characterize The Diastereomer Composition of Oligonucleotide Therapeutics for Advancing New and Generic Drug Development

This workshop will discuss the analytical challenges associated with characterizing the diastereomer composition of oligonucleotide therapeutics and explore advancements in both analytical and statistical methods to overcome these limitations. The focus will be on the use of specific examples involving FDA-approved drugs and synthetic analogues to demonstrate the value of integrating analytical methods with validated statistics.

Highlights:

- Discuss the limitations and advantages of using multiple analytical methods to evaluate the diastereomer composition in oligonucleotide therapeutics
- Statistical evaluation of approved drug products to synthetic analogues for comparing diastereomer composition
- Discuss the role synthetic chemistry plays in biasing diastereomer composition

Workshop Leaders

Michael P. Cummings
Professor of Biology & Director of the Center for Bioinformatics & Computational Biology
University of Maryland

Jace W. Jones
Associate Professor, Department of Pharmaceutical Sciences, School Pharmacy
University of Maryland

End of Pre-Conference Workshop Day 4.00

Conference Day One
Wednesday, December 10

8.00 Morning Coffee & Check-in

8.55 Chair's Opening Remarks

Advancing Extrahepatic Delivery: Current Innovations Enabling Targeted Therapeutics Beyond the Liver for Enhanced Clinical Outcomes

9.00 **Panel Discussion: Turning Setbacks into Strategy, what Clinical Trial Failures Teach us About Building Better Oligonucleotide Therapies**

- Unpack the reasons behind trial discontinuations: Was it the oligo, delivery system, or something else?
- Identify overlooked red flags in preclinical models, PK data, or target biology that led to setbacks
- Discuss how teams rebounded, what pivots, partnerships, or reformulations turned failure into future success


Hagen Cramer
Chief Technology Officer
QurAlis


Marcin Kortylewski
Professor
City of Hope


David Guay
Vice President - Innovation & Technology
Feldan Therapeutics


Jack Ostrowski
Director, Protein Science
Avidity Biosciences

10.00 **Delivering to Muscle, Systemic Approaches for Metabolic & Neuromuscular Indications**

- Outlining Opportunities with systemic delivery to overcome long-standing barriers in biodistribution and unlocking new therapeutic potential
- Exploring Naked antisense oligos with activity in the muscle
- Novel methods of targeting, previously undruggable targets, expanding the scope of oligonucleotide therapeutics

10.30 Morning break & Speed Networking
The ideal opportunity to get face-to-face with many of the leading experts in oligonucleotide development who are working from within discovery all the way through to late-stage clinical development and engage with attendees for important in-depth conversations.


Frank Jaschinski
Chief Executive Officer
Secarna

11.30 **Modulation of the Tumor Microenvironment Using Antisense Oligonucleotides**

- Tumors actively shape their microenvironment to promote angiogenesis, metastasis, and immune evasion, creating conditions that support their growth and resistance to therapy
- Neuropilin-1 (NRP1) is broadly expressed across multiple cell types within the tumor microenvironment, where it simultaneously facilitates these pro-tumorigenic processes
- Antisense oligonucleotides (ASOs) designed to silence NRP1 expression effectively reduce its levels in key cellular compartments, leading to potent antitumor activity both as a monotherapy and in combination with immune checkpoint inhibitors


Tama Evron
Director, Platform Discovery
Dyne Therapeutics

12.00 **Outlining the FORCE Platform: Innovations to Enhance Oligonucleotide Delivery to Muscle Tissues**

- How Dyne's Force platform is enhancing delivery of oligos to muscle tissues
- Properties and modularity of the FORCE Platform
- Provide evidence of translation between pre-clinical models and clinical proof of concept with DYNE-101


Cody Desjardins
Senior Director
Dyne Therapeutics

12.30 **CNS Delivery Frontiers, Enabling Oligonucleotide Therapeutics for Neurological Disorders**

- Latest innovations in crossing the blood–brain barrier with oligonucleotide drugs
- Design considerations for enabling safe and effective CNS delivery

1.00 Lunch break & Networking

Conference Day One
Wednesday, December 10

Engineering Smarter Oligonucleotides, Unlocking Chemical Designs that Enhance Selectivity, Potency & Stability

Meena Indrakanti
Senior Vice President, Translational DMPK & Clinical Pharmacology
Stoke Therapeutics

2.00 **Utilization of Oligonucleotides' Half-Life to Optimize Dosing Regimen for Desirable Efficacy & Reduced CNS Toxicity**

- Explore how chemical modifications and structural engineering can make oligos more resistant to nuclease degradation
- Understand the impact of half-life extension on dosing frequency, therapeutic window, and patient compliance
- Learn how conjugation to long-circulating carriers like antibodies can enhance PK/PD profiles and tissue retention

Jean-Christophe Hoflack
Senior Principal Scientist
F Hoffmann-La Roche

2.30 **Detection and Risk Assessment of Hybridization-Mediated Off-Targets of oligonucleotide Therapeutics: Case Studies, Current Industry Recommendations, & Future Perspectives**

- Detection and risk assessment of hybridization-mediated off-targets of oligonucleotide therapeutics
- Current strategic recommendations from an industrial perspective
- Pending challenges and need for enhanced specificity and selectivity

3.00 **Afternoon Break & Scientific Poster Session**
This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of biopharma experts eager to hear the latest innovations in oligonucleotide Therapeutics, you will have the opportunity to display a poster presenting your own research.

Utsav Saxena
Head of Systems Biology
Novo Nordisk

4.00 **Assessing & Improving Specificity of Therapeutic siRNAs in Preclinical Models**

- Review how small chemical tweaks can dramatically improve target engagement and hybridization kinetics
- Unpack the structural features that drive binding specificity and reduce unwanted interactions with non-target transcripts
- Explore screening methods and predictive tools to de-risk oligo designs before clinical translation

Santhosh Kumar
Senior Principal Scientist
Genentech

4.30 **Advancing Oligonucleotide Therapeutics Through Innovative Chemistry, Novel siRNA designs for Improved Delivery & Biodistribution**

- Engineering next-generation oligonucleotide platforms to overcome delivery barriers, enhance intracellular uptake, and achieve durable therapeutic knockdown
- Developing innovative chemical modifications to enhance stability, potency, safety and improve the overall therapeutic index of oligonucleotide therapeutics

5.00 **Chair's Closing Remarks**

Conference Day Two
Thursday, December 11

8.00 **Morning Coffee & Check-in**

8.55 **Chair's Opening Remarks**

9.00 **Panel Discussion: Overcoming Design Challenges in Next-Generation Oligonucleotides to Maximize Selectivity, Potency & Clinical Impact**

- What design strategies are most effective in mitigating off-target effects?
- How do teams prioritize stability vs. delivery vs. potency?
- What are the emerging trends in oligonucleotide chemistry for next-generation therapeutics?

Ganesh Iyer
Chief Executive Officer & Founder
Oppртna Therapeutics

Pawan Kumar
Director, Oligonucleotide Chemistry
Biomarin

Emerging Modalities, Innovative Technologies Enabling Diverse Therapeutic Strategies for Enhanced Disease Targeting

Ganesh Iyer
Chief Executive Officer & Founder
Oppртna Therapeutics

10.00 **Aptamers: Precision Intracellular Modulators Offering Targeted Protein Control Beyond Gene Silencing**

- Overview of aptamer structure and target binding capabilities inside cells
- Challenges in chemical stability and strategies to improve molecular retention in vivo
- Potential for success, sharing success stories in the therapeutic space, rather than just the diagnostic space

10.30 **Morning break & Networking**

Marcin Kortylewski
Professor
City of Hope

11.30 **Cancer Immunotherapy Using RNA Aptamers for Cell-Selective Delivery or Intracellular Target Inhibition**

- Expanding therapeutic horizons of aptamers beyond conventional targets on cell surface
- Leveraging innovative oligonucleotide chemistries to enable novel cancer treatment strategies
- Advancing conjugation technologies to enhance delivery and address complex myeloid cell biology

David Guay
Vice President - Innovation & Technology
Feldan Therapeutics

12.00 **Optimizing Therapeutic Success, Choosing the Right Oligonucleotide & Delivery Vehicle for Precise Target Engagement**

- Comparative overview of ASOs, siRNA, and aptamers: mechanisms of action, strengths, and limitations
- Key decision-making factors: target accessibility, disease indication, and delivery constraints
- Matching modalities with delivery strategies for optimal pharmacokinetics and tissue specificity

12.30 **Lunch & Networking**

+1 617 455 4188 info@hansonwade.com
www. oligonucleotide-based-therapeutics.com

Conference Day Two
Thursday, December 11

Innovating Biomarkers, Unlocking Novel Targets & Overcoming Manufacturing Hurdles to Drive Clinical Advancement

Hagen Cramer
Chief Technology Officer
QurAlis

1.30 **Navigating CMC Complexity: Overcoming Manufacturing & Cost Barriers to Advance Next-Generation Oligonucleotide Therapeutics**

- Why multi-component designs present unique manufacturing and regulatory hurdles to understand the CMC burden of novel oligos
- New approaches to reduce cost and complexity: Including, enzymatic ligation, and emerging scalable manufacturing technologies
- Building global manufacturing readiness: Evaluating current capacity and capabilities to meet growing demand for large-scale, GMP-compliant oligonucleotide production

Safety & Toxicity, Overcoming Development Challenges to Deliver Safer, Longer-Lasting Oligonucleotide Therapeutics

Speaker from NanoVation

2.00 **Formulating the Right Lipid Nanoparticle, Minimizing Toxicity While Maximizing Delivery Efficiency**

- Key factors driving LNP toxicity and how to address them in formulation design
- Case examples of successful LNP engineering for improved safety profiles
- Balancing stability, delivery performance, and tolerability in clinical candidates

David Parfitt
Senior Scientist
ProQR Therapeutics

2.30 **Strategies to Improve the Safety of Oligonucleotide Delivery to the Brain to Mitigate CNS Toxicity**

- Mechanisms underlying neurotoxicity in CNS-directed oligonucleotide delivery
- Preclinical models and predictive approaches for early toxicity detection
- Practical mitigation strategies for formulation and dosing optimization

3.00 **Chair's Closing Remarks**

3.05 **End of Conference**

"Speakers and participants were experts in the field so it was great to connect and learn. Duration of each talk was perfect so as to stay engaged without being overwhelming"

Principal Scientist, Biogen

"Networking opportunities and robust audience engagement."

Principal Consultant, ex FDA

"Excellent and very relevant topics. The meeting format allowed for networking and sharing experiences."

Head, Drug Development, Fuku Biotech

Partner With Us

Position Your Expertise at the Forefront of Next-Gen Oligonucleotide Therapeutics

This meeting will bring together the key decision-makers shaping the future of RNA-based medicines. As a partner, you'll position your company at the forefront of this fast-moving field, building meaningful partnerships, showcasing your expertise, and aligning your brand with the innovators driving oligo programs from early discovery through to the clinic.

Engage with a Highly Targeted Audience

Put your brand in front of senior leaders in oligonucleotide chemistry, delivery, CMC, safety, and regulatory strategy who are urgently seeking partners that can solve challenges around capacity, timelines, bioavailability, and quality to move programs forward.

Showcase Your Chemistry, Delivery & Development Expertise

Demonstrate how your solutions in innovative oligo design, precision delivery, and scalable manufacturing directly address industry bottlenecks such as long wait times, off-target effects, and the difficulty of scaling candidates into the clinic.

Position Your Brand as a Trusted, Strategic Partner

Build credibility as the go-to collaborator who can deliver on what matters most to drug developers: competitive cost, predictable timelines, transparency, and uncompromising quality, while advancing safer, more effective RNA-based medicines.

Companies who have attended Hanson Wade Oligonucleotide Conference Series

AVIDITY BIOSCIENCES, Biogen, City of Hope, Dyne Therapeutics, Feldan Therapeutics, Genentech, novo nordisk®
Opprtna Therapeutics, Orbital Therapeutics, QurAlis, Regeneron, Roche, Secarna, Stoke Therapeutics
Alnylam, Apellis, arrowhead pharmaceuticals, BioMarin, CAMP4, Denali Therapeutics, GSK
Ionis, Johnson&Johnson, Lilly, Novartis, ProQR Therapeutics, Switch Therapeutics, Takeda

Get Involved

Jamie Redmond
Senior Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www. oligonucleotide-based-therapeutics.com/take-part/register/

Tel: US +1 617 455 4188 / EU +44 (0)20 3141 8700

Email: info@hansonwade.com

DISCOVER the latest innovations in oligonucleotide chemistry, precision delivery, and scalable manufacturing, and learn how leading teams are overcoming critical challenges in bioavailability, off-target effects, and clinical translation.

LEARN practical strategies to navigate regulatory expectations, optimize safety and toxicity testing, and address capacity and timeline bottlenecks, with real-world case studies from industry leaders and vendors.

CONNECT with senior decision-makers, expert vendors, and cross-functional teams to share insights, build trusted partnerships, and accelerate the development of safe, effective, and next-generation RNA-based therapies.

Drug Developer Pricing	Register & Pay By Friday, September 26 to save $900	On the Door Price
Conference + Pre-Conference Workshop Day	$3,297	$4,197
Conference Only	$2,499	$2,999

Academic/ Not-for-Profit Pricing	Register & Pay By Friday, September 26 to save $900	On the Door Price
Conference + Pre-Conference Workshop Day	$2,697	$3,597
Conference Only	$2,099	$2,599

Standard Pricing	Register & Pay By Friday, September 26 to save $900	On the Door Price
Conference + Pre-Conference Workshop Day	$4,197	$5,097
Conference Only	$3,199	$3,699

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- **10% discount – 3 Attendees**
- **15% discount – 4 Attendees**
- **20% discount – 5+ Attendees**

***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Hotel Commonwealth

500 Commonwealth Ave, Boston, MA 02215, United States

https://www.hotelcommonwealth.com/

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom